Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients

Loading news article.

Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients | WAPE

Article summary